English
简体中文
Total: £ 56.28
Published Date: 2025-09-15 | Pages: 125 | Tables: 115 | Pharma & Healthcare
The global market for Meningococcal Vaccine was estimated to be worth US$ 285 million in 2024 and is forecast to a readjusted size of US$ 384 million by 2031 with a CAGR of 4.4% during the forecast period 2025-2031.
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.
In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.
This report aims to provide a comprehensive presentation of the global market for Meningococcal Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Meningococcal Vaccine by region & country, by Type, and by Application.
The Meningococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (10K Pcs) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Vaccine.
Market Segmentation
By Company
Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Segment by Type
Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Meningococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Meningococcal Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Meningococcal Vaccine Product Introduction
1.2 Global Meningococcal Vaccine Market Size Forecast
1.2.1 Global Meningococcal Vaccine Sales Value (2020-2031)
1.2.2 Global Meningococcal Vaccine Sales Volume (2020-2031)
1.2.3 Global Meningococcal Vaccine Sales Price (2020-2031)
1.3 Meningococcal Vaccine Market Trends & Drivers
1.3.1 Meningococcal Vaccine Industry Trends
1.3.2 Meningococcal Vaccine Market Drivers & Opportunity
1.3.3 Meningococcal Vaccine Market Challenges
1.3.4 Meningococcal Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Meningococcal Vaccine Players Revenue Ranking (2024)
2.2 Global Meningococcal Vaccine Revenue by Company (2020-2025)
2.3 Global Meningococcal Vaccine Players Sales Volume Ranking (2024)
2.4 Global Meningococcal Vaccine Sales Volume by Company Players (2020-2025)
2.5 Global Meningococcal Vaccine Average Price by Company (2020-2025)
2.6 Key Manufacturers Meningococcal Vaccine Manufacturing Base and Headquarters
2.7 Key Manufacturers Meningococcal Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Meningococcal Vaccine
2.9 Meningococcal Vaccine Market Competitive Analysis
2.9.1 Meningococcal Vaccine Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Meningococcal Vaccine Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Vaccine as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Meningtits A
3.1.2 Polysaccharide Meningtitis AC
3.1.3 Meningitis ACYW
3.2 Global Meningococcal Vaccine Sales Value by Type
3.2.1 Global Meningococcal Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Meningococcal Vaccine Sales Value, by Type (2020-2031)
3.2.3 Global Meningococcal Vaccine Sales Value, by Type (%) (2020-2031)
3.3 Global Meningococcal Vaccine Sales Volume by Type
3.3.1 Global Meningococcal Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Meningococcal Vaccine Sales Volume, by Type (2020-2031)
3.3.3 Global Meningococcal Vaccine Sales Volume, by Type (%) (2020-2031)
3.4 Global Meningococcal Vaccine Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 6 Months-15Year
4.1.2 over 3 Year
4.1.3 over 2 Year
4.1.4 over 3 Months
4.2 Global Meningococcal Vaccine Sales Value by Application
4.2.1 Global Meningococcal Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Meningococcal Vaccine Sales Value, by Application (2020-2031)
4.2.3 Global Meningococcal Vaccine Sales Value, by Application (%) (2020-2031)
4.3 Global Meningococcal Vaccine Sales Volume by Application
4.3.1 Global Meningococcal Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Meningococcal Vaccine Sales Volume, by Application (2020-2031)
4.3.3 Global Meningococcal Vaccine Sales Volume, by Application (%) (2020-2031)
4.4 Global Meningococcal Vaccine Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Meningococcal Vaccine Sales Value by Region
5.1.1 Global Meningococcal Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Meningococcal Vaccine Sales Value by Region (2020-2025)
5.1.3 Global Meningococcal Vaccine Sales Value by Region (2026-2031)
5.1.4 Global Meningococcal Vaccine Sales Value by Region (%), (2020-2031)
5.2 Global Meningococcal Vaccine Sales Volume by Region
5.2.1 Global Meningococcal Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Meningococcal Vaccine Sales Volume by Region (2020-2025)
5.2.3 Global Meningococcal Vaccine Sales Volume by Region (2026-2031)
5.2.4 Global Meningococcal Vaccine Sales Volume by Region (%), (2020-2031)
5.3 Global Meningococcal Vaccine Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Meningococcal Vaccine Sales Value, 2020-2031
5.4.2 North America Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Meningococcal Vaccine Sales Value, 2020-2031
5.5.2 Europe Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Meningococcal Vaccine Sales Value, 2020-2031
5.6.2 Asia Pacific Meningococcal Vaccine Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Meningococcal Vaccine Sales Value, 2020-2031
5.7.2 South America Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Meningococcal Vaccine Sales Value, 2020-2031
5.8.2 Middle East & Africa Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Meningococcal Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Meningococcal Vaccine Sales Value
6.2.1 Key Countries/Regions Meningococcal Vaccine Sales Value, 2020-2031
6.2.2 Key Countries/Regions Meningococcal Vaccine Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Meningococcal Vaccine Sales Value, 2020-2031
6.3.2 United States Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Meningococcal Vaccine Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Meningococcal Vaccine Sales Value, 2020-2031
6.4.2 Europe Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Meningococcal Vaccine Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Meningococcal Vaccine Sales Value, 2020-2031
6.5.2 China Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
6.5.3 China Meningococcal Vaccine Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Meningococcal Vaccine Sales Value, 2020-2031
6.6.2 Japan Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Meningococcal Vaccine Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Meningococcal Vaccine Sales Value, 2020-2031
6.7.2 South Korea Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Meningococcal Vaccine Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Meningococcal Vaccine Sales Value, 2020-2031
6.8.2 Southeast Asia Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Meningococcal Vaccine Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Meningococcal Vaccine Sales Value, 2020-2031
6.9.2 India Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
6.9.3 India Meningococcal Vaccine Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Company Information
7.1.2 Novartis Introduction and Business Overview
7.1.3 Novartis Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Novartis Meningococcal Vaccine Product Offerings
7.1.5 Novartis Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Introduction and Business Overview
7.2.3 GSK Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 GSK Meningococcal Vaccine Product Offerings
7.2.5 GSK Recent Development
7.3 Merck
7.3.1 Merck Company Information
7.3.2 Merck Introduction and Business Overview
7.3.3 Merck Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Merck Meningococcal Vaccine Product Offerings
7.3.5 Merck Recent Development
7.4 CSL
7.4.1 CSL Company Information
7.4.2 CSL Introduction and Business Overview
7.4.3 CSL Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 CSL Meningococcal Vaccine Product Offerings
7.4.5 CSL Recent Development
7.5 Baxter
7.5.1 Baxter Company Information
7.5.2 Baxter Introduction and Business Overview
7.5.3 Baxter Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Baxter Meningococcal Vaccine Product Offerings
7.5.5 Baxter Recent Development
7.6 JN International Medical Corporation
7.6.1 JN International Medical Corporation Company Information
7.6.2 JN International Medical Corporation Introduction and Business Overview
7.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 JN International Medical Corporation Meningococcal Vaccine Product Offerings
7.6.5 JN International Medical Corporation Recent Development
7.7 Serum Institute of India
7.7.1 Serum Institute of India Company Information
7.7.2 Serum Institute of India Introduction and Business Overview
7.7.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Serum Institute of India Meningococcal Vaccine Product Offerings
7.7.5 Serum Institute of India Recent Development
7.8 Bio-Med
7.8.1 Bio-Med Company Information
7.8.2 Bio-Med Introduction and Business Overview
7.8.3 Bio-Med Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Bio-Med Meningococcal Vaccine Product Offerings
7.8.5 Bio-Med Recent Development
7.9 China National Biotec Group
7.9.1 China National Biotec Group Company Information
7.9.2 China National Biotec Group Introduction and Business Overview
7.9.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 China National Biotec Group Meningococcal Vaccine Product Offerings
7.9.5 China National Biotec Group Recent Development
7.10 Hualan Bio
7.10.1 Hualan Bio Company Information
7.10.2 Hualan Bio Introduction and Business Overview
7.10.3 Hualan Bio Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Hualan Bio Meningococcal Vaccine Product Offerings
7.10.5 Hualan Bio Recent Development
7.11 Walvax
7.11.1 Walvax Company Information
7.11.2 Walvax Introduction and Business Overview
7.11.3 Walvax Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Walvax Meningococcal Vaccine Product Offerings
7.11.5 Walvax Recent Development
7.12 Zhifei
7.12.1 Zhifei Company Information
7.12.2 Zhifei Introduction and Business Overview
7.12.3 Zhifei Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Zhifei Meningococcal Vaccine Product Offerings
7.12.5 Zhifei Recent Development
8 Industry Chain Analysis
8.1 Meningococcal Vaccine Industrial Chain
8.2 Meningococcal Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Meningococcal Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Meningococcal Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Meningococcal Vaccine Market Trends
Table 2. Meningococcal Vaccine Market Drivers & Opportunity
Table 3. Meningococcal Vaccine Market Challenges
Table 4. Meningococcal Vaccine Market Restraints
Table 5. Global Meningococcal Vaccine Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Meningococcal Vaccine Revenue Market Share by Company (2020-2025)
Table 7. Global Meningococcal Vaccine Sales Volume by Company (2020-2025) & (10K Pcs)
Table 8. Global Meningococcal Vaccine Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Meningococcal Vaccine Price by Company (2020-2025) & (USD/Pcs)
Table 10. Key Manufacturers Meningococcal Vaccine Manufacturing Base and Headquarters
Table 11. Key Manufacturers Meningococcal Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Meningococcal Vaccine
Table 13. Global Meningococcal Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Vaccine as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Meningococcal Vaccine Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Meningococcal Vaccine Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Meningococcal Vaccine Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Meningococcal Vaccine Sales Market Share in Value by Type (2020-2025)
Table 20. Global Meningococcal Vaccine Sales Market Share in Value by Type (2026-2031)
Table 21. Global Meningococcal Vaccine Sales Volume by Type: 2020 VS 2024 VS 2031 (10K Pcs)
Table 22. Global Meningococcal Vaccine Sales Volume by Type (2020-2025) & (10K Pcs)
Table 23. Global Meningococcal Vaccine Sales Volume by Type (2026-2031) & (10K Pcs)
Table 24. Global Meningococcal Vaccine Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Meningococcal Vaccine Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Meningococcal Vaccine Price by Type (2020-2025) & (USD/Pcs)
Table 27. Global Meningococcal Vaccine Price by Type (2026-2031) & (USD/Pcs)
Table 28. Global Meningococcal Vaccine Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Meningococcal Vaccine Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Meningococcal Vaccine Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Meningococcal Vaccine Sales Market Share in Value by Application (2020-2025)
Table 32. Global Meningococcal Vaccine Sales Market Share in Value by Application (2026-2031)
Table 33. Global Meningococcal Vaccine Sales Volume by Application: 2020 VS 2024 VS 2031 (10K Pcs)
Table 34. Global Meningococcal Vaccine Sales Volume by Application (2020-2025) & (10K Pcs)
Table 35. Global Meningococcal Vaccine Sales Volume by Application (2026-2031) & (10K Pcs)
Table 36. Global Meningococcal Vaccine Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Meningococcal Vaccine Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Meningococcal Vaccine Price by Application (2020-2025) & (USD/Pcs)
Table 39. Global Meningococcal Vaccine Price by Application (2026-2031) & (USD/Pcs)
Table 40. Global Meningococcal Vaccine Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Meningococcal Vaccine Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Meningococcal Vaccine Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Meningococcal Vaccine Sales Value by Region (2020-2025) & (%)
Table 44. Global Meningococcal Vaccine Sales Value by Region (2026-2031) & (%)
Table 45. Global Meningococcal Vaccine Sales Volume by Region (10K Pcs): 2020 VS 2024 VS 2031
Table 46. Global Meningococcal Vaccine Sales Volume by Region (2020-2025) & (10K Pcs)
Table 47. Global Meningococcal Vaccine Sales Volume by Region (2026-2031) & (10K Pcs)
Table 48. Global Meningococcal Vaccine Sales Volume by Region (2020-2025) & (%)
Table 49. Global Meningococcal Vaccine Sales Volume by Region (2026-2031) & (%)
Table 50. Global Meningococcal Vaccine Average Price by Region (2020-2025) & (USD/Pcs)
Table 51. Global Meningococcal Vaccine Average Price by Region (2026-2031) & (USD/Pcs)
Table 52. Key Countries/Regions Meningococcal Vaccine Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Meningococcal Vaccine Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Meningococcal Vaccine Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Meningococcal Vaccine Sales Volume, (2020-2025) & (10K Pcs)
Table 56. Key Countries/Regions Meningococcal Vaccine Sales Volume, (2026-2031) & (10K Pcs)
Table 57. Novartis Company Information
Table 58. Novartis Introduction and Business Overview
Table 59. Novartis Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 60. Novartis Meningococcal Vaccine Product Offerings
Table 61. Novartis Recent Development
Table 62. GSK Company Information
Table 63. GSK Introduction and Business Overview
Table 64. GSK Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 65. GSK Meningococcal Vaccine Product Offerings
Table 66. GSK Recent Development
Table 67. Merck Company Information
Table 68. Merck Introduction and Business Overview
Table 69. Merck Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 70. Merck Meningococcal Vaccine Product Offerings
Table 71. Merck Recent Development
Table 72. CSL Company Information
Table 73. CSL Introduction and Business Overview
Table 74. CSL Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 75. CSL Meningococcal Vaccine Product Offerings
Table 76. CSL Recent Development
Table 77. Baxter Company Information
Table 78. Baxter Introduction and Business Overview
Table 79. Baxter Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 80. Baxter Meningococcal Vaccine Product Offerings
Table 81. Baxter Recent Development
Table 82. JN International Medical Corporation Company Information
Table 83. JN International Medical Corporation Introduction and Business Overview
Table 84. JN International Medical Corporation Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 85. JN International Medical Corporation Meningococcal Vaccine Product Offerings
Table 86. JN International Medical Corporation Recent Development
Table 87. Serum Institute of India Company Information
Table 88. Serum Institute of India Introduction and Business Overview
Table 89. Serum Institute of India Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 90. Serum Institute of India Meningococcal Vaccine Product Offerings
Table 91. Serum Institute of India Recent Development
Table 92. Bio-Med Company Information
Table 93. Bio-Med Introduction and Business Overview
Table 94. Bio-Med Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 95. Bio-Med Meningococcal Vaccine Product Offerings
Table 96. Bio-Med Recent Development
Table 97. China National Biotec Group Company Information
Table 98. China National Biotec Group Introduction and Business Overview
Table 99. China National Biotec Group Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 100. China National Biotec Group Meningococcal Vaccine Product Offerings
Table 101. China National Biotec Group Recent Development
Table 102. Hualan Bio Company Information
Table 103. Hualan Bio Introduction and Business Overview
Table 104. Hualan Bio Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 105. Hualan Bio Meningococcal Vaccine Product Offerings
Table 106. Hualan Bio Recent Development
Table 107. Walvax Company Information
Table 108. Walvax Introduction and Business Overview
Table 109. Walvax Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 110. Walvax Meningococcal Vaccine Product Offerings
Table 111. Walvax Recent Development
Table 112. Zhifei Company Information
Table 113. Zhifei Introduction and Business Overview
Table 114. Zhifei Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 115. Zhifei Meningococcal Vaccine Product Offerings
Table 116. Zhifei Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Meningococcal Vaccine Downstream Customers
Table 120. Meningococcal Vaccine Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Meningococcal Vaccine Product Picture
Figure 2. Global Meningococcal Vaccine Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Meningococcal Vaccine Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Meningococcal Vaccine Sales Volume (2020-2031) & (10K Pcs)
Figure 5. Global Meningococcal Vaccine Sales Price (2020-2031) & (USD/Pcs)
Figure 6. Meningococcal Vaccine Report Years Considered
Figure 7. Global Meningococcal Vaccine Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Meningococcal Vaccine Players Sales Volume Ranking (2024) & (10K Pcs)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Meningococcal Vaccine Revenue in 2024
Figure 10. Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Meningtits A Picture
Figure 12. Polysaccharide Meningtitis AC Picture
Figure 13. Meningitis ACYW Picture
Figure 14. Global Meningococcal Vaccine Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 15. Global Meningococcal Vaccine Sales Value Market Share by Type, 2024 & 2031
Figure 16. Global Meningococcal Vaccine Sales Volume by Type (2020 VS 2024 VS 2031) & (10K Pcs)
Figure 17. Global Meningococcal Vaccine Sales Volume Market Share by Type, 2024 & 2031
Figure 18. Global Meningococcal Vaccine Price by Type (2020-2031) & (USD/Pcs)
Figure 19. Product Picture of 6 Months-15Year
Figure 20. Product Picture of over 3 Year
Figure 21. Product Picture of over 2 Year
Figure 22. Product Picture of over 3 Months
Figure 23. Global Meningococcal Vaccine Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 24. Global Meningococcal Vaccine Sales Value Market Share by Application, 2024 & 2031
Figure 25. Global Meningococcal Vaccine Sales Volume by Application (2020 VS 2024 VS 2031) & (10K Pcs)
Figure 26. Global Meningococcal Vaccine Sales Volume Market Share by Application, 2024 & 2031
Figure 27. Global Meningococcal Vaccine Price by Application (2020-2031) & (USD/Pcs)
Figure 28. North America Meningococcal Vaccine Sales Value (2020-2031) & (US$ Million)
Figure 29. North America Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
Figure 30. Europe Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 31. Europe Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
Figure 32. Asia Pacific Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Meningococcal Vaccine Sales Value by Region (%), 2024 VS 2031
Figure 34. South America Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 35. South America Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
Figure 36. Middle East & Africa Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 37. Middle East & Africa Meningococcal Vaccine Sales Value by Country (%), 2024 VS 2031
Figure 38. Key Countries/Regions Meningococcal Vaccine Sales Value (%), (2020-2031)
Figure 39. Key Countries/Regions Meningococcal Vaccine Sales Volume (%), (2020-2031)
Figure 40. United States Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 41. United States Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
Figure 42. United States Meningococcal Vaccine Sales Value by Application (%), 2024 VS 2031
Figure 43. Europe Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 44. Europe Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
Figure 45. Europe Meningococcal Vaccine Sales Value by Application (%), 2024 VS 2031
Figure 46. China Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 47. China Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
Figure 48. China Meningococcal Vaccine Sales Value by Application (%), 2024 VS 2031
Figure 49. Japan Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 50. Japan Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
Figure 51. Japan Meningococcal Vaccine Sales Value by Application (%), 2024 VS 2031
Figure 52. South Korea Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 53. South Korea Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
Figure 54. South Korea Meningococcal Vaccine Sales Value by Application (%), 2024 VS 2031
Figure 55. Southeast Asia Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 56. Southeast Asia Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
Figure 57. Southeast Asia Meningococcal Vaccine Sales Value by Application (%), 2024 VS 2031
Figure 58. India Meningococcal Vaccine Sales Value, (2020-2031) & (US$ Million)
Figure 59. India Meningococcal Vaccine Sales Value by Type (%), 2024 VS 2031
Figure 60. India Meningococcal Vaccine Sales Value by Application (%), 2024 VS 2031
Figure 61. Meningococcal Vaccine Industrial Chain
Figure 62. Meningococcal Vaccine Manufacturing Cost Structure
Figure 63. Channels of Distribution (Direct Sales, and Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
